Harrison K. Tsai

Harrison K. Tsai

Auto-generated profile, based on publicly available information

Harrison K. Tsai

Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2020 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
HTHarrison K. Tsai
Harrison K. Tsai
DBDiane G. Brackett
Diane G. Brackett
DSDavid Szeto
David Szeto
RFRyan Frazier
Ryan Frazier
AMAllison MacLeay
Allison MacLeay
VNValentina Nardi
Valentina Nardi
Assessment of internal tandem duplications in FLT3 (FLT3-ITDs) and their allelic ratio (AR) is recommended by clinical guidelines for diagnostic workup of acute myeloid leukemia and traditionally performed through capillary electrophoresis (CE). Although significant progress has been made integrating FLT3-ITD detection within contemporary next-generation sequencing (NGS) panels, AR estimation is not routinely part of clinical NGS practice because of inherent biases and challenges. In this study, data from multiple NGS platforms—anchored multiplex PCR (AMP), amplicon [TruSeq Custom Amplicon (TSCA)], and hybrid-capture—were analyzed through a custom algorithm, including platform-specific measures of AR. Sensitivity and specificity of NGS for FLT3-ITD status relative to CE were 100% (42/42) and 99.4% (1076/1083), respectively, by AMP on an unselected cohort and 98.1% (53/54) and 100% (48/48), respectively, by TSCA on a selected cohort. Primer analysis identified criteria for ITDs to escape detection by TSCA, estimated to occur in approximately 9% of unselected ITDs. Allelic fractions under AMP or TSCA were highly correlated to CE, with linear regression slopes near 1 for ITDs not duplicating primers, and systematically underestimated for ITDs duplicating a primer. Bias was alleviated in AMP through simple adjustments. This article provides an approach for targeted computational FLT3-ITD analysis for NGS data from multiple platforms; AMP was found capable of near perfect sensitivity and specificity with relatively accurate estimates of ARs.

30 September 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
SSStephanie E. Siegmund
Stephanie E. Siegmund
LSLynette Sholl
Lynette Sholl
HTHarrison K. Tsai
Harrison K. Tsai
YYYiying Yang
Yiying Yang
VVVarshini Vasudevaraja
Varshini Vasudevaraja
AAAndres Martin Acosta
Andres Martin Acosta

3 May 2024 in Laboratory Investigation
Verified
Journal Article
Closed access
HTHarrison K. Tsai
Harrison K. Tsai
MSMark F. Sabbagh
Mark F. Sabbagh
MMMeagan Montesion
Meagan Montesion
EWErik A. Williams
Erik A. Williams
AAArnaldo Arbini
Arnaldo Arbini
JBJacob R. Bledsoe
Jacob R. Bledsoe

29 June 2023 in Haematologica
Verified
Journal Article
Open access
PDF file
SMSarah B. Mueller
Sarah B. Mueller
YPYana Pikman
Yana Pikman
STSarah K. Tasian
Sarah K. Tasian
LSLewis B. Silverman
Lewis B. Silverman
MHMarian H. Harris
Marian H. Harris
HTHarrison K. Tsai
Harrison K. Tsai

5 July 2023 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
HTHarrison K. Tsai
Harrison K. Tsai
TGTasos Gogakos
Tasos Gogakos
VLVa Lip
Va Lip
JTJonathan M. Tsai
Jonathan M. Tsai
YLYen-Der Li
Yen-Der Li
MHMarian Harris
Marian Harris

19 September 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JPJonathan Paolino
Jonathan Paolino
BDBoris Dimitrov
Boris Dimitrov
BWBeth Apsel Winger
Beth Apsel Winger
ASAngelica Sandoval-Perez
Angelica Sandoval-Perez
ARAmith Vikram. Rangarajan
Amith Vikram. Rangarajan
YPYana Pikman
Yana Pikman
Purpose: Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) have limited therapeutic options. Clinical use of genomic profiling provides an opportunity to identify targetable alterations to inform therapy. Experimental Design: We describe a cohort of 14 pediatric patients with relapsed or refractory T-ALL enrolled on the Leukemia Precision-based Therapy (LEAP) Consortium trial (NCT02670525) and a patient with T-LBL, discovering alterations in platelet-derived growth factor receptor-α (PDGFRA) in 3 of these patients. We identified a novel mutation in PDGFRA, p.D842N, and used an integrated structural modeling and molecular biology approach to characterize mutations at D842 to guide therapeutic targeting. We conducted a preclinical study of avapritinib in a mouse patient-derived xenograft (PDX) model of FIP1L1-PDGFRA and PDGFRA p.D842N leukemia. Results: Two patients with T-ALL in the LEAP cohort (14%) had targetable genomic alterations affecting PDGFRA, a FIP1-like 1 protein/PDGFRA (FIP1L1-PDGFRA) fusion and a novel mutation in PDGFRA, p.D842N. The D842N mutation resulted in PDGFRA activation and sensitivity to tested PDGFRA inhibitors. In a T-ALL PDX model, avapritinib treatment led to decreased leukemia burden, significantly prolonged survival, and even cured a subset of mice. Avapritinib treatment was well tolerated and yielded clinical benefit in a patient with refractory T-ALL. Conclusions: Refractory T-ALL has not been fully characterized. Alterations in PDGFRA or other targetable kinases may inform therapy for patients with refractory T-ALL who otherwise have limited treatment options. Clinical genomic profiling, in real time, is needed for fully informed therapeutic decision making.